Amy S Ruppert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2209064/publications.pdf

Version: 2024-02-01

63	2,998	331670	175258
papers	citations	21 h-index	52 g-index

63	63	63	4146
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Strategies to Account for Design Misspecifications in Randomized Controlled Trials. , 2022, 1, .		0
2	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. Leukemia, 2022, 36, 2129-2131.	7.2	3
3	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 2021, 35, 3287-3290.	7.2	0
4	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 766-774.	0.4	4
5	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia, 2021, 35, 2854-2861.	7.2	12
6	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. Nature Communications, 2021, 12, 6338.	12.8	3
7	Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status. Blood, 2021, 138, 1563-1563.	1.4	0
8	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. Blood, 2021, 138, 639-639.	1.4	27
9	Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. Blood, 2021, 138, 523-523.	1.4	14
10	Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leukemia and Lymphoma, 2020, 61, 387-396.	1.3	29
11	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-NaÃ¯ve and Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 3626-3637.	1.6	71
12	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood, 2020, 135, 2041-2048.	1.4	158
13	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood, 2020, 136, 2-3.	1.4	1
14	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	1.4	12
15	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.. Journal of Clinical Oncology, 2020, 38, 8042-8042.	1.6	4
16	Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.. Journal of Clinical Oncology, 2020, 38, e20004-e20004.	1.6	0
17	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 22-23.	1.4	1
18	A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 27-30.	1.4	1

#	Article	IF	Citations
19	Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1993-2001.	2.0	10
20	Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. Circulation: Cardiovascular Imaging, 2019, 12, e008777.	2.6	22
21	Second cancer incidence in CLL patients receiving BTK inhibitors.. Journal of Clinical Oncology, 2019, 37, 7511-7511.	1.6	2
22	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).. Journal of Clinical Oncology, 2019, 37, 7544-7544.	1.6	3
23	Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD). , 2019, 2, 079-082.		0
24	A singleâ€institution retrospective cohort study of firstâ€line Râ€<scp>EPOCH</scp> chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. British Journal of Haematology, 2018, 180, 259-266.	2.5	53
25	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	27.0	706
26	Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs. Contemporary Clinical Trials Communications, 2018, 12, 40-50.	1.1	6
27	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). Blood, 2018, 132, 146-146.	1.4	6
28	Depth of response and progression free survival in CLL patients on ibrutinib.. Journal of Clinical Oncology, 2018, 36, 7514-7514.	1.6	2
29	Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2018, 36, 7528-7528.	1.6	1
30	A Retrospective Study of Clinical and Laboratory Characteristics in Patients Diagnosed with Platelet Storage Pool Deficiency. Blood, 2018, 132, 1148-1148.	1.4	0
31	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. Blood, 2018, 132, 2878-2878.	1.4	0
32	Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. Journal of Immunology, 2017, 198, 2500-2512.	0.8	43
33	Frequency and clinical correlates of elevated plasma Epsteinâ€Barr virus DNA at diagnosis in peripheral Tâ€cell lymphomas. International Journal of Cancer, 2017, 140, 1899-1906.	5.1	15
34	Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. Leukemia and Lymphoma, 2017, 58, 1589-1597.	1.3	2
35	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Advances, 2017, 1, 1739-1748.	5.2	123
36	The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget, 2017, 8, 25942-25954.	1.8	23

#	Article	IF	Citations
37	DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nature Genetics, 2016, 48, 253-264.	21.4	254
38	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. Blood, 2016, 128, 1215-1215.	1.4	25
39	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic LImphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. Blood, 2016, 128, 4388-4388.	1.4	2
40	Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 639-639.	1.4	22
41	Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia. Blood, 2016, 128, 968-968.	1.4	4
42	Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 28684-28696.	1.8	9
43	Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy and Pharmacology, 2015, 76, 1005-1012.	2.3	3
44	Proteomic profiling identifies specific histone species associated with leukemic and cancer cells. Clinical Proteomics, 2015, 12, 22.	2.1	18
45	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. British Journal of Haematology, 2015, 170, 200-207.	2.5	8
46	SomaticMED12mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget, 2015, 6, 1884-1888.	1.8	49
47	Epigenetic silencing of miR-708 enhances NF-Î¹B signaling in chronic lymphocytic leukemia. International Journal of Cancer, 2015, 137, 1352-1361.	5.1	52
48	TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2169-2174.	7.1	63
49	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncology, 2015, 1, 80.	7.1	498
50	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 278-285.e1.	0.4	19
51	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4322-4327.	7.1	38
52	Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2436-2436.	1.4	1
53	The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2911-2911.	1.4	2
54	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2951-2951.	1.4	10

#	Article	IF	Citations
55	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2953-2953.	1.4	2
56	Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. Blood, 2015, 126, 3983-3983.	1.4	5
57	Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). Blood, 2015, 126, 4328-4328.	1.4	0
58	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leukemia Research, 2014, 38, 1025-1029.	0.8	11
59	Brutonâ€™s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood, 2014, 123, 1207-1213.	1.4	176
60	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood, 2014, 123, 1810-1817.	1.4	246
61	Utilization of EBV DNA Copy Number Monitoring in Extranodal NK Lymphoma, Nasal Type in Non Asian Patients. Blood, 2012, 120, 5088-5088.	1.4	0
62	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. Blood, 2012, 120, 3865-3865.	1.4	0
63	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. Journal of Clinical Oncology, 2011, 29, 1349-1355.	1.6	124